Works matching IS 15391604 AND DT 2023 AND VI 22 AND IP 1

Results: 15

A Bayesian phase I/II design to determine subgroup‐specific optimal dose for immunotherapy sequentially combined with radiotherapy.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 143, doi. 10.1002/pst.2265

By:

Guo, Beibei;
Zang, Yong;
Lin, Li‐Hsiang;
Zhang, Rui

Publication type:

Article

Treatment effect measures under nonproportional hazards.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 181, doi. 10.1002/pst.2267

By:

Snapinn, Steven;
Jiang, Qi;
Ke, Chunlei

Publication type:

Article

A meta‐analytic framework to adjust for bias in external control studies.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 162, doi. 10.1002/pst.2266

By:

Incerti, Devin;
Bretscher, Michael T.;
Lin, Ray;
Harbron, Chris

Publication type:

Article

An adaptive biomarker basket design in phase II oncology trials.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 128, doi. 10.1002/pst.2264

By:

Liu, Shufang;
Takeda, Kentaro;
Rong, Alan

Publication type:

Article

A comparison of statistical methods for animal oncology studies.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 112, doi. 10.1002/pst.2263

By:

Zhang, Tianhui;
Novick, Steven J.

Publication type:

Article

Should the two‐trial paradigm still be the gold standard in drug assessment?

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 96, doi. 10.1002/pst.2262

By:

Zhan, Stella Jinran;
Kunz, Cornelia Ursula;
Stallard, Nigel

Publication type:

Article

A model selection criterion for clustered survival analysis with informative cluster size.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 79, doi. 10.1002/pst.2261

By:

Chien, Li‐Chu;
Chang, Li‐Ying;
Shen, Chung‐Wei

Publication type:

Article

Sensitivity analyses for the principal ignorability assumption using multiple imputation.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 64, doi. 10.1002/pst.2260

By:

Wang, Craig;
Zhang, Yufen;
Mealli, Fabrizia;
Bornkamp, Björn

Publication type:

Article

Setting the control limit at release for stability assurance.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 45, doi. 10.1002/pst.2259

By:

Chen, X. Gregory;
van der Vaart, A. W.

Publication type:

Article

Key considerations for choosing a statistical method to deal with incomplete treatment adherence in pragmatic trials.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 205, doi. 10.1002/pst.2258

By:

Hossain, Md. Belal;
Karim, Mohammad Ehsanul

Publication type:

Article

Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 194, doi. 10.1002/pst.2257

By:

Jin, Yanling;
Ton, Thanh G. N.;
Incerti, Devin;
Hu, Sylvia

Publication type:

Article

A Bayesian piecewise exponential phase II design for monitoring a time‐to‐event endpoint.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 34, doi. 10.1002/pst.2256

By:

Qing, Yun;
Thall, Peter F.;
Yuan, Ying

Publication type:

Article

Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomes.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 20, doi. 10.1002/pst.2251

By:

Dong, Gaohong;
Huang, Bo;
Verbeeck, Johan;
Cui, Ying;
Song, James;
Gamalo‐Siebers, Margaret;
Wang, Duolao;
Hoaglin, David C.;
Seifu, Yodit;
Mütze, Tobias;
Kolassa, John

Publication type:

Article

Propensity score matching and stratification using multiparty data without pooling.

Published in:

Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 4, doi. 10.1002/pst.2250

By:

Wang, Jixian;
Marion‐Gallois, Roland

Publication type:

Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2023, v. 22, n. 1, p. 1, doi. 10.1002/pst.2235
Publication type:: Article